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Sickle cell disease (SCD) is an inherited blood disorder which can
be complicated by stroke in infancy and childhood. The primary
and secondary prevention of stroke in this patient population is
regular RBC transfusion therapy at least every three weeks, but
there is no consensus on the ideal RBC transfusion therapy. The
Charles Drew Program, a partnership among a blood center and
several hospitals affiliated with academic medical centers in
Missouri, provides RBCs for the care of patients with SCD. There
are three basic aims: the RBC components are phenotypically
matched on three minor RBC antigens, the units are less than 7 days
old, and each patient has a limited number of dedicated donors, so
that the donor exposure is minimized. This report describes the
operational phases of this program and summarizes its
performance with respect to each of these aims.
Immunohematology 2006;22:112–116.
Sickle cell disease (SCD) is an inherited blood
disorder that predominantly affects African Americans.
Among children with sickle cell anemia (HbSS),
approximately 11 percent will have a stroke and
approximately 10 percent will have an elevated
transcranial Doppler measurement, indicating that they
are at increased risk for strokes. For both primary and
secondary prevention of strokes, chronic transfusion
therapy is required for an indefinite period.1
However, there is no consensus on the ideal
chronic transfusion protocol. The lack of such a
protocol results in a higher than acceptable rate of
complications associated with commonly monthly RBC
transfusions,such as the high rate of alloimmunization.2
In a recent survey investigating the chronic transfusion
protocols of North American laboratories,
approximately two-thirds of these laboratories
performed no phenotype testing beyond the required
ABO and D testing, and among the institutions in the
remaining one-third, approximately 85 percent
performed a limited phenotype match.3 Other
components of blood transfusion therapy programs
that have not been formally assessed include the
potential benefit of transfusing fresh units (< 7 days)
and limiting donor exposure.
Program History and Protocol
The Drew Program began in 1999 as a partnership
among the Missouri/Illinois Region of the American
Red Cross (ARC) and several hospitals in Missouri
specializing in the care of pediatric patients. The
program has three objectives. The first objective is to
provide phenotypically matched, hemoglobin S (HbS)-
negative, leukoreduced RBCs to all pediatric patients
with sickle cell anemia who require chronic trans-
fusion therapy and are participating in the program. All
patients receive units with a limited phenotype match
(C, E, and K in addition to ABO and D). Studies
supporting this practice have been published in the
scientific literature.2,4 One transfusion service requests
that the units also be matched for Fya. Any patient who
develops an antibody receives units which are negative
for the antigenic determinant against which the
antibody is directed. The second objective is to ensure
The Charles Drew Program in
Missouri: a description of a
partnership among a blood center
and several hospitals to address
the care of patients with sickle
cell disease
E.J. ISAAK, B. LECHIEN,T. LINDSEY,AND M.R. DEBAUN
I M M U N O H E M A T O L O G Y, V O L U M E  2 2 , N U M B E R  3 , 2 0 0 6 113
Charles Drew Program
that these units are fresh with the goal of limiting the
interval from collection to transfusion to a period of
five days. The third objective is to limit the number of
donors to which each patient is exposed.
Recruitment Process
Blood drives are held in conjunction with donor
groups with a significant African American base. When
this base accounts for 30 percent of the donor group
membership, the drive is designated as a Drew drive.
Donor groups with this type of demographic make-up
consist of churches, corporations, and schools. Before
a Drew drive, a dedicated donor recruiter educates the
group about the sickle cell program, its purpose, and
the requirements for participation. At the time of the
drive, this dedicated recruiter, or one of a few hand-
picked designees, has a one-on-one interview with any
donor expressing an interest in becoming a member of
the program. A realistic picture of the program
requirements is presented to the donor, who can then
make a more informed decision about whether a
commitment to the stringent requirements of the
program can be made. If the donor still expresses an
interest after the interview, the unit which they donate
is specially tagged, so that it can be phenotyped. On
the basis of the phenotype, the donor is matched with
one of the patients in the program and is placed on a
recruitment list for that single patient. When the
patient has an upcoming appointment, the donors on
the patient’s list are called and asked to donate within
a short window of time (commonly 5 days) before the
scheduled treatment date. Donors accepting the
responsibility of joining the program are expected to
donate a minimum of three times per year.
Communication between Transfusion
Service and Blood Center
Each transfusion service sends a list of scheduled
transfusions along with the expected number of units
needed for each patient to the blood center every
month. This list is essential to the two departments at
the blood center which coordinate most of the
program activities: donor recruitment and the
reference lab. The recruiters use these patient
schedules to guide the selection of donors and to select
an appropriate appointment date. All units intended
for patients in the program are channeled to the blood
center reference lab, which is ultimately responsible
for appropriate distribution of the units to the
transfusion services. With the first donation from a
given donor, two tags are affixed to the unit at the time
of distribution. The first tag indicates for whom the
unit is intended; the second tag lists the confirmed
antigens. Subsequent donations from the same donor
are only tagged with the name of the recipient and a
fax is sent to the hospital indicating the historical
phenotype of the donor. The reference lab maintains
an open dialogue with the hospital transfusion services
during this distribution and during the period which
follows. Patient issues and product issues are resolved
through this open dialogue. At the conclusion of each
month, the reference lab sends a complete report of all
units issued during that month to every transfusion
service. Next to each listed unit, the transfusion service
notes whether the unit was transfused to the intended
recipient and when it was transfused. The transfusion
service also notes any units the patient may have
received which came from a source outside of the
program. The report is then returned to the reference
lab, which collects all the information and generates a
complete transfusion history on each of the patients in
the program.
Donor Profiles
The Missouri/Illinois Region of the ARC is a large
blood center that collected an average of 287,097
productive units per year (range 259,160–310,614)
between July 1998 and June 2005 (Table 1). During the
same period, the average number of those productive
units donated by individuals identifying themselves as
African Americans was 11,088 per year (range 8,616-
13,420). The difference between the number of
donations from African Americans from July 1998 to
June 1999 and from July 2000 to June 2001 was
attributed to increased minority recruitment efforts
and to increased community awareness concurrent
with the initiation of the Drew Program. Donation
Table 1. Productive RBC units collected by the Missouri/Illinois Region
of the ARC from July 1998 through June 2005
Units from Units from 
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frequency within the dedicated donor base (those
donating three times per year or more) is illustrated in
Table 2.
Transfusion Service and Patient
Characteristics
There are four pediatric hospitals serving patients
with sickle cell anemia. Among the four hospitals,
there are three that participate in the Drew Program.
The remaining hospital receives phenotyped units
without restriction on the age of the units or the
number of donor exposures. Because the three
hospitals participating in the Drew Program are all
affiliated with academic centers, many of the patients
in the program came as referrals because of
complications at outside institutions,and some of these
patients had already formed antibodies before they
joined the program. The current phenotypes of the
patients in the program and the antibodies formed by
the patients are listed in Table 3.
In addition to the special requirements with
respect to phenotype, age, and donor exposure, the
donors in the program are placed on treatment
protocols involving some form of exchange RBC
transfusion, either partial manual exchange or RBC
apheresis, to prevent the issues associated with iron
overload. The distribution of patients receiving each
form of treatment is outlined in Table 4.
Program Performance
From 1999 to January 2005, the program
concentrated on the first objective of the protocol;
implementation of the second and third objectives
required a critical mass of dedicated donors. Beginning
in January 2005, modifications in program design were
made so that the operational progress of the program
could be monitored and assessed through the use 
of a monthly productivity report. The
productivity report requires documen-
tation of the requested number of units,
the number of scheduled donations to
fill that request, the number of calls
required to make those scheduled
donations, and the outcome of those
scheduled donations for each patient
requiring transfusion therapy in that
month. For all successful donations,
the day of collection and the day of
distribution are documented. This
allows the program to maintain data on
the number of patients transfused, the
number of units each patient requires,
the number of scheduled appointments
needed to meet that commitment,
the number of calls needed to make 
the requisite number of scheduled
appointments, the number of deferrals
and cancellations, the number of 
Table 2. Donation frequency of donors in Charles Drew Program from
July 2003 through June 2005
7/03–6/04 7/04–6/05
7 times per year 0 1
6 times per year 15 13
5 times per year 58 69
4 times per year 91 147
3 times per year 229 229
2 times per year 408 345
once per year 668 520
Total 1,469 1,324
Table 4. Transfusion protocols used to treat patients in the Charles Drew
Program*
Number of patients
Simple Partial RBC exchange
Hospital 1 0 8 10
Hospital 2 0 0 6
Hospital 3 0 15 11
*Currently, two patients have had their transfusions suspended.
Table 3. Patient phenotypes and antibodies produced in patients in the Charles Drew Program
Number of Number of
Patient patients with patients who
phenotype phenotype produced antibody Common Low frequency
C–,E–,K– 15 7 -E, -K, -S, -Jkb –










C–,K– 7 3 -K (2) –
– Ytb
E–,K–,Fy(a–) 7 1 – Goa
E–,K– 5 2 -Jkb –
-D –
C–,K–,Fy(a–) 3 0 – –
D–,C–,E–,K– 2 1 -D, -C –
K– 2 1 -M –
*Each antibody was produced once unless otherwise noted.
Antibodies produced*
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no-shows, and the age of the units at the time of
distribution. The performance of the program with
respect to fill rate and age of units at distribution is
illustrated in Table 5.
Because the program is still actively accruing
donors, the orders from the hospitals are not always
filled with units from donors who have been accepted
into the program. Until the program has accrued a
sufficient number of donors to meet this requirement,
the balance of the order is filled with random
allogeneic units which meet all the phenotyping
requirements. The element missing when these
random units are used is the restriction on the number
of donors. For those units coming from donors
participating in the program, the operational
procedures are usually successful in ensuring that the
units are fresh.
Beginning in February 2005, a pilot project was
performed as a feasibility study to determine how
successful the program could be at fulfilling the third
objective of the protocol. An attempt was made to
limit the donor exposure for 12 of the patients at two
of the hospitals. The results of this pilot project have
been submitted for publication. Overall, within the
first year,donor exposure was reduced by an average of
45 percent based on the performance of the blood
center. Because of additional logistic variables at the
hospitals, this resulted in an overall reduction in donor
exposure of 32 percent at one hospital and 37 percent
at the other.
Discussion
Since its inception in 1999, the Drew Program has
tried to meet three objectives in the delivery of care to
the patients with sickle cell anemia who require
chronic transfusion therapy. The first objective has
been met, and all patients in the program receive HbS-
negative, leukoreduced RBCs which are phenotypically
matched. Two protocols are used. In one of the
protocols, the patients receive units that are
phenotypically matched for C, E, and K. In the second
protocol, the units are also matched for Fya. On the
basis of the antibody profile of the patients in the
program as indicated in Table 5 and consistent with
previous reporting in other publications, these two
matching protocols would have prevented the majority
of clinically significant antibody-related complications.4
The program regularly meets the second objective
and the average age of the units is often 5 days. The
rationale for this objective is the belief that the
frequency of transfusion therapy may be reduced if the
transfused RBCs are closer to the beginning of their
shelf life. Since the patients require regular transfusion
therapy, this objective may help to minimize the
disruptions that therapy causes in the lives of these
patients. While this reasoning sounds plausible, this
assumption has not been investigated and validated.
The program has been working on the third
objective since February 2005. The rationale behind
this objective is that minimizing donor exposure may
reduce the rate of alloimmunization. Transfusion is a
recognized form of immunization, but in some
instances, it may induce immunologic tolerance. The
capacity of transfusion to induce immunologic
tolerance has been used to treat women with recurrent
abortions and patients receiving solid-organ
transplants.5,6 Tolerance may be the result of induction
of CD4+ regulatory T cells, and there is evidence that
this effect may depend on the degree of HLA-DR
matching between donor and recipient, the presence
of co-stimulatory molecules, and possibly on the
presence of leukocytes within the transfused
Table 5. Effectiveness of the Charles Drew Program
Units requested Units sent Average age of units (days)
Date Hospital 1 Hospital 2 Hospital 3 Hospital 1 Hospital 2 Hospital 3 Hospital 1 Hospital 2 Hospital 3
Aug 2005 68 15 67 57 7 65 5 6 4
Sep 2005 73 6 63 54 6 63 5 4 6
Oct 2005 58 6 60 42 6 59 5 5 5
Nov 2005 64 12 68 46 4 66 7 N/A 6
Dec 2005 70 11 82 40 6 82 6 7 5
Jan 2006 64 12 83 50 14 81 5 6 5
Feb 2006 58 27 74 45 12 73 5 6 4
Mar 2006 64 25 93 65 12 89 7 9 5
Apr 2006 60 17 76 52 17 76 6 6 5
Totals 579 131 666 451 84 654 N/A N/A N/A
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component.7,8 At this point the phenomenon is
incompletely understood, and the determination of the
clinical value in reducing donor exposure merits
investigation and clarification. The recently completed
pilot project showed that donor exposure can be
significantly reduced; the clinical value of this
reduction may take several years to document.
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